natgillin/translations-raw huggingface dataset:
Co-administration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.
Istodobna primjena fentanila i serotonergičkih lijekova, kao što su selektivni inhibitor ponovne pohrane serotonina (SSRI), ili inhibitor ponovne pohrane serotonina i noradrenalina (SNRI), ili inhibitor monoamino oksidaze (MAOI), može povećati rizik od serotoninskog sindroma, stanje koje može biti po život opasno.
Co-administration of Firazyr with angiotensin-converting-enzyme (ACE) inhibitors has not been studied.
Nije proučavana istodobna primjena Firazyra s inhibitorima angiotenzin konvertirajućeg enzima (ACE).
Co-administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.
Istodobna primjena flukonazola ili izavukonazola moţe povisiti koncentracije tenofoviralafenamida u plazmi.
Co-administration of Genvoya and other medicinal products primarily metabolised by CYP3A such as amiodarone, quinidine, cisapride, pimozide, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see section 4.3).
Kontraindicirana je i istodobna primjena lijeka Genvoya i drugih lijekova koje prvenstveno metabolizira CYP3A, kao što su amiodaron, kinidin, cisaprid, pimozid, alfuzosin i sildenafil za plućnu arterijsku hipertenziju (vidjeti dio 4.3).
Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g., simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally administered midazolam or triazolam).
Istodobna primjena lijeka Genvoya i nekih lijekova koje prvenstveno metabolizira CYP3A može rezultirati povećanim koncentracijama tih lijekova u plazmi, koje su povezane s potencijalno teškim ili životno opasnim nuspojavama, kao što su periferni vazospazam ili ishemija (npr. dihidroergotamin, ergotamin, ergometrin) ili miopatija, uključujući i rabdomiolizu (npr. simvastatin, lovastatin) ili dugotrajna ili povećana sedacija ili respiratorna depresija (npr. midazolam primijenjen peroralno, triazolam).
Co-administration of Genvoya and some medicinal products that induce CYP3A such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital, and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Istodobna primjena lijeka Genvoya i nekih lijekova koji induciraju CYP3A, kao što su gospina trava (Hypericum perforatum), rifampicin, karbamazepin, fenobarbital i fenitoin, može dovesti do značajno smanjenih koncentracija kobicistata i elvitegravira u plazmi, što može za posljedicu imati gubitak terapijskog učinka i razvoj rezistencije (vidjeti dio 4.3).
Co-administration of Harvoni with oxcarbazepine is expected to decrease the concentration of ledipasvir and sofosbuvir leading to reduced therapeutic effect of Harvoni.
Očekuje se da će istovremena primjena lijeka Harvoni s okskarbazepinom smanjiti koncentraciju ledipasvira i sofosbuvira i tako dovestido smanjenog terapijskog učinka lijeka Harvoni.
Co-administration of Harvoni with pravastatin may significantly increase the concentration of pravastatin which is associated with increased risk of myopathy.
Istodobna primjena lijeka Harvoni s pravastatinom može značajno povećatikoncentraciju pravastatina, što je povezano s povećanim rizikom od miopatije.
Co-administration of Harvoni with rosuvastatin is contraindicated (see section 4.3).
Istovremena primjena lijeka Harvoni s rosuvastatinomje kontraindicirana (vidjeti dio 4.3).
Co-administration of Harvoni with rosuvastatin may significantly increase the concentration of rosuvastatin (severalfold-increase in AUC) which is associated with increased risk of myopathy, including rhabdomyolysis.
Istodobna primjena lijeka Harvoni s rosuvastatinom može značajno povećatikoncentraciju rosuvastatina (AUC povećana nekoliko puta), što je povezano s povećanim rizikom od miopatije, uključujući rabdomiolizu.
Co-administration of higher doses of either efavirenz or carbamazepine has not been studied.
Istovremena primjena viših doza efavirenza ili karbamazepina nije ispitana.
Co-administration of IKERVIS with eye drops containing corticosteroids could potentiate the effects of ciclosporin on the immune system (see section 4.4).
Istovremena primjena IKERVISA s kapima za oči koje sadrže kortikosteroide može pojačati djelovanje ciklosporina na imunološki sustav (vidjeti dio 4.4).
Co-administration of IKERVIS with eye drops containing corticosteroids could potentiate the effects of IKERVIS on the immune system (see section 4.5).
Istovremena primjena IKERVISA s kapima za oči koje sadrže kortikosteroide može pojačati djelovanje IKERVISA na imunološki sustav (vidjeti dio 4.5).
Co-administration of INCIVO and medicinal products that inhibit CYP3A and/or P-gp may increase telaprevir plasma concentrations.
Istodobna primjena INCIVA i lijekova koji inhibiraju CYP3A i/ili P-gp može povisiti koncentracije telaprevira u plazmi.
Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure  to valsartan.
Istodobna primjena inhibitora prijenosnika unosa (rifampicin, ciklosporin) ili efluksnog prijenosnika  (ritonavir) može povećati sistemsku izloženost valsartanu.
Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.
Istodobna primjena inhibitora prijenosnika unosa (rifampicin, ciklosporin) ili efluksnog prijenosnika  (ritonavir) može povećati sistemsku izloženost valsartanu.
Co-administration of INTELENCE and medicinal products that inhibit CYP3A4, CYP2C9 or CYP2C19 may decrease the clearance of etravirine and may result in increased plasma concentrations of etravirine.
Istovremena primjena INTELENCEa i lijekova koji inhibiraju CYP3A4, CYP2C9 ili CYP2C19 može smanjiti klirens etravirina, što može rezultirati povećanom koncentracijom etravirina u plazmi.
Co-administration of INTELENCE with medicinal products primarily metabolised by CYP3A4 may result in decreased plasma concentrations of such medicinal products, which could decrease or shorten their therapeutic effects.
Istovremena primjena INTELENCEa s lijekovima koje primarno metabolizira izoenzim CYP3A4 može rezultirati smanjenom koncentracijom tih lijekova u plazmi, što bi moglo smanjiti ili skratiti njihove terapijske učinke.
Co-administration of intravenous 5-HT3 receptor antagonists with oral paracetamol in human subjects has been reported to result in a block in the analgesic effect via a pharmacodynamic mechanism.
Istovremena intravenska primjena antagonista 5-HT3 receptora i peroralnog paracetamola u ljudskim ispitanicima blokirala je analgetski učinak putem farmakodinamičkog mehanizma.
Co-administration of IntronA with ribavirin increased the efficacy of IntronA by at least two fold for the treatment of chronic heptatitis C in naïve patients.
Primjena lijeka IntronA zajedno s ribavirinom povećala je najmanje dvostruko djelotvornost lijeka IntronA u liječenju kroničnog hepatitisa C u bolesnika koji prethodno nisu bili liječeni.
Co-administration of INVEGA 12 mg once daily with divalproex sodium prolonged-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.
Istovremena primjena INVEGE od 12 mg jednom dnevno i tableta divalproeksnatrija s produljenim oslobađanjem (500 mg do 2000 mg jednom dnevno) nije utjecala na farmakokinetiku valproata u stanju dinamičke ravnoteže.
Co-administration of ISENTRESS with a calcium carbonate antacid decreased raltegravir plasma levels; however, this interaction is not considered clinically meaningful.
Istodobna primjena lijeka ISENTRESS s antacidom koji sadrži kalcijev karbonat snizila je koncentraciju raltegravira u plazmi; međutim, ta se interakcija ne smatra klinički značajnom.
Co-administration of ISENTRESS with aluminium and magnesium antacids resulted in reduced raltegravir plasma levels.
Istodobna primjena lijeka ISENTRESS s antacidima koji sadrže aluminij i magnezij rezultirala je sniženim koncentracijama raltegravira u plazmi.
Co-administration of ISENTRESS with aluminium and/or magnesium antacids is not recommended (see section 4.5).
Istodobna primjena lijeka ISENTRESS s antacidima koji sadrže aluminij i/ili magnezij se ne preporučuje (vidjeti dio 4.5).
Co-administration of ISENTRESS with antacids containing divalent metal cations may reduce raltegravir absorption by chelation, resulting in a decrease of raltegravir plasma levels.
Istodobna primjena lijeka ISENTRESS s antacidima koji sadrže dvovalentne katione metala može kelacijom smanjiti apsorpciju raltegravira i tako dovesti do sniženja koncentracije raltegravira u plazmi.
Co-administration of ISENTRESS with medicinal products that are known to be potent UGT1A1 inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir.
Istodobna primjena lijeka ISENTRESS s lijekovima za koje se zna da su potentni inhibitori UGT1A1 (npr. atazanavir) može povisiti koncentraciju raltegravira u plazmi.
Co-administration of ISENTRESS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 1).
Istodobna primjena lijeka ISENTRESS s drugim lijekovima koji povisuju želučani pH (npr. omeprazolom i famotidinom) može povećati stopu apsorpcije raltegravira i dovesti do povišenja koncentracije raltegravira u plazmi (vidjeti Tablicu 1).
Co-administration of ISENTRESS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 2).
Istodobna primjena lijeka ISENTRESS s drugim lijekovima koji povisuju želučani pH (npr. omeprazolom i famotidinom) može povećati stopu apsorpcije raltegravira i dovesti do povišenja koncentracije raltegravira u plazmi (vidjeti Tablicu 2).
Co-administration of ISENTRESS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 3).
Istodobna primjena lijeka ISENTRESS s drugim lijekovima koji povisuju želučani pH (npr. omeprazolom i famotidinom) može povećati stopu apsorpcije raltegravira i dovesti do povišenja koncentracije raltegravira u plazmi (vidjeti Tablicu 3).
Co-administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased M1 to a lesser extent than ivacaftor.
Istovremena primjena ivakaftora s rifampicinom, jakim induktorom CYP3A, smanjila je izloženost ivakaftoru (AUC) za 89%, i smanjila izloženost M1 u manjoj mjeri nego ivakaftoru.
Co-administration of Kaletra and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse reactions.
Istodobna primjena lijeka Kaletra i lijekova koji se metaboliziraju prvenstveno putem CYP3A može izazvati povišenje njihovih koncentracija u plazmi te tako pojačati ili produžiti njihovo djelovanje i nuspojave.
Co-administration of Kaletra with
Istodobna primjena lijeka Kaletra i
Co-administration of Kaletra with these medicinal products is expected to substantially increase their concentrations and may result in associated adverse events such as hypotension, syncope, visual changes and prolonged erection (see section 4.5).
Istodobna primjena lijeka Kaletra s ovim lijekovima može znatno povećati njihove koncentracije u krvi i rezultirati pratećim štetnim događajima kao što su hipotenzija, sinkopa, promjene vida i produžena erekcija (vidjeti dio 4.5).
Co-administration of ketoconazole (200 mg), a potent CYP3A4 inhibitor, with vardenafil (5 mg) resulted in a 10-fold increase in vardenafil AUC and a 4-fold increase in vardenafil Cmax (see section 4.4).
Istodobna primjena ketokonazola (200 mg), jakog inhibitora CYP3A4, s vardenafilom (5 mg) rezultirala je 10-strukim povećanjem AUC vardenafila i 4-strukim povećanjem Cmax vardenafila (vidjeti dio 4.4).
Co-administration of Ketoconazole HRA and other medications known to have potentially hepatotoxic effect (eg paracetamol) is not recommended since the combination may lead to increased risk of liver damage.
Ne preporučuje se istovremena primjena Ketoconazolea HRA i drugih lijekova za koje je poznato da imaju potencijalno hepatotoksični učinak (npr. paracetamol) jer njihova kombinacija može povećati rizik od oštećenja jetre.
Co-administration of Ketoconazole HRA and pasireotide is not recommended since the combination can lead to QT prolongation in patients with known cardiac rhythm disorders (see section 4.5).
Ne preporučuje se istovremena primjena Ketoconazolea HRA i pasireotida jer njihova kombinacija u bolesnika s utvrđenim poremećajem srčanog ritma može uzrokovati produljenje QT intervala (vidjeti dio 4.5).
Co-administration of ketoconazole, a strong CYP3A4 inhibitor, in 18 fasted healthy subjects, increased exposure (Cmax and AUC) of ibrutinib by 29- and 24-fold, respectively.
Istodobna primjena ketokonazola, snažnog CYP3A4 inhibitora, u 18 zdravih ispitanika natašte, povećala je izloženost ibrutinibu (Cmax 29 puta i AUC 24 puta).
Co-administration of lamivudine with food results in a delay of tmax and a lower C max (decreased by 47 %).
Istovremena primjena lamivudina s hranom odgađa tmax i smanjuje Cmax (smanjuje se do 47%).
Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis should be avoided.
Treba izbjegavati istodobnu primjenu lamivudina s visokim dozama kotrimoksazola u liječenju pneumonije uzrokovane Pneumocystis carinii (PCP) i toksoplazmoze.
Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis should be avoided.
Treba izbjegavati istodobnu primjenu lamivudina s visokim dozama kotrimoksazola u liječenju pneumonije uzrokovane Pneumocystis carinii i toksoplazmoze.
Co-administration of lamivudine with OCT and MATE inhibitors could increase lamivudine exposure.
Istodobna primjena lamivudina s inhibitorima OCT i MATE može povećati izloženost lamivudinu.
Co-administration of lithium and Actelsar HCT is not recommended.
Istodobna primjena litija i Actelsara HCT se ne preporučuje.
Co-administration of lithium and Kinzalkomb is not recommended (see section 4.4).
Istodobna primjena litija i Konzalkomba se ne preporučuje (vidjeti dio 4.4).
Co-administration of lithium and PritorPlus is not recommended (see section 4.4).
Istodobna primjena litija i PritorPlusa se ne preporučuje (vidjeti dio 4.4).
Co-administration of loop diuretics and non-steroidal anti-inflammatory drugs can result in a decreased natriuretic response.
Istovremena primjena diuretika Henleove petlje i nesteroidnih protuupalnih lijekova može izazvati smanjen natriuretski odgovor.
Co-administration of lopinavir/ritonavir and Atripla is not recommended.
Ne preporučuje se istovremena primjena lopinavira/ritonavira s Atriplom.
Co-administration of maraviroc with
Istodobna primjena maraviroka i
Co-administration of maraviroc with St.
Istodobna primjena maraviroka i
Co-administration of medicinal products that act as potent inducers of both CYP1A2 and the other CYP isoenzymes involved in the metabolism of pirfenidone (e.g. rifampicin) may result in significant lowering of pirfenidone plasma levels.
Istodobna primjena lijekova koji mogu djelovati kao snažni induktori CYP1A2 i drugih izoenzima CYP uključenih u metabolizam pirfenidona (npr. rifampicina) može uzrokovati značajno sniženje razine pirfenidona u plazmi.
Co-administration of medicinal products that are substrates of CYP3A and have narrow therapeutic indeces and for which elevated plasma concentrations are associated with serious and/or life- threatening events are contraindicated with EVOTAZ.
Kontraindicirana je istodobna primjena lijeka EVOTAZ i lijekova koji su supstrati za CYP3A i imaju uzak terapijski indeks i čije se povišene plazmatske koncentracije povezuju s ozbiljnim i/ili po život opasnim događajima.
Co-administration of medicinal products which are inducers of CYP3A4 and/or CYP3A5 may decrease the plasma concentrations of isavuconazole.
Istodobna primjena lijekova koji su induktori CYP3A4 i/ili CYP3A5 moţe sniziti koncentracije izavukonazola u plazmi.
Co-administration of medicinal products which are inhibitors of CYP3A4 and/or CYP3A5 may increase the plasma concentrations of isavuconazole.
Istodobna primjena lijekova koji su inhibitori CYP3A4 i/ili CYP3A5 moţe povećati koncentracije izavukonazola u plazmi.
Co-administration of medicinal products which cause folate deficiency (e.g. sulphonamides, trimethoprim-sulphamethoxazole) can lead to increased methotrexate toxicity.
Istovremena primjena lijekova koji uzrokuju nedostatak folata (npr. sulfonamidi, trimetoprim- sulfamethoksazol) mogu dovesti do povećane toksičnosti metotreksata.
Co-administration of medicinal products with serotonergic effect (e.g., tramadol, sumatriptan and other triptans) may lead to Serotonin Syndrome (see section 4.4).
Istodobna primjena lijekova sa serotonergičkim učinkom (npr., tramadol, sumatriptan i drugi triptani) može dovesti do serotoninskog sindroma (vidjeti dio 4.4).
Co-administration of micafungin and amphotericin B desoxycholate should only be used when the benefits clearly outweigh the risks, with close monitoring of amphotericin B desoxycholate toxicities (see section 4.5).
Mikafungin i amfotericin B dezoksikolat smiju se istodobno primjenjivati samo kad koristi jasno premašuju rizike, s time da treba pažljivo pratiti toksičnost amfotericin B dezoksikolata (vidjeti dio 4.5).
Co-administration of moxifloxacin and delamanid in MDR-TB patients has not been studied.
Istovremena primjena moksifloksacina i delamanida u bolesnika s MDR-TB nije proučavana.
Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.
Istodobna primjena višekratnih doza od 10 mg amlodipina s 80 mg simvastatina rezultirala je povećanjem izloženosti simvastatinu za 77% u usporedbi sa samim simvastatinom.
Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
Istodobna primjena ponovljenih doza od 10 mg lenalidomida nije imala učinka na farmakokinetiku pojedinačne doze R- i S- varfarina.
Co-administration of multiple doses of amlodipine with simvastatin 80 mg resulted in an increase in exposure to simvastatin up to 77 % compared to simvastatin alone.
Istodobna primjena višestrukih doza amlodipina i simvastatina od 80 mg rezultirala je povećanjem izloženosti simvastatinu do 77 % u usporedbi s monoterapijom simvastatina.
Co-administration of multiple doses of idelalisib 150 mg twice daily to healthy subjects resulted in comparable exposures for rosuvastatin (AUC 90% CI: 87, 121) and digoxin (AUC 90% CI: 98, 111), suggesting no clinically relevant inhibition of BCRP, OATP1B1/1B3 or systemic P-gp by idelalisib.
Istovremena primjena višestrukih doza idelalisiba od 150 mg dva puta dnevno u zdravih ispitanika dovela je do izloženosti rosuvastatinu (AUC 90% CI: 87, 121) usporedive s izloženošću digoksinu (AUC 90% CI: 98, 111), što ukazuje na to da idelalisib nije klinički značajan inhibitor BCRP, OATP1B1/1B3 ili sistemskog P-gp.
Co-administration of neuroleptics with cobicistat may result in increased plasma concentrations of neuroleptics.
Istovremena primjena neuroleptika s kobicistatom može za posljedicu imati povećane koncentracije neuroleptika u plazmi.
Co-administration of nevirapine and cobicistat is expected to decrease cobicistat plasma concentrations.
Očekuje se da će istovremena primjena nevirapina i kobicistata smanjiti koncentracije kobicistata u plazmi.
Co-administration of nevirapine and elvitegravir is expected to decrease elvitegravir plasma concentrations which may result in loss of therapeutic effect and possible development of resistance.
Istovremena primjena nevirapina i elvitegravira očekivano smanjuje koncentracije elvitegravira u plazmi, što može rezultirati gubitkom terapijskog učinka i mogućim razvojem rezistencije.
Co-administration of Nevirapine Teva with elvitegravir in combination with cobicistat is not recommended (see section 4.4).
Istodobna primjena Nevirapina Teva s elvitegravirom u kombinaciji s kobicistatom se ne preporučuje (vidjeti dio 4.4).
Co-administration of NSAIDs and cyclosporin or tacrolimus has been suggested to increase the nephrotoxic effect of cyclosporin and tacrolimus because of NSAID effects on renal prostaglandins.
Spomenuto je da istodobna primjena nesteroidnih protuupalnih lijekova i ciklosporina ili takrolimusa povećava nefrotoksične učinke ciklosporina i takrolimusa zbog učinka nesteroidnih protuupalnih lijekova na bubrežne prostaglandine.
Co-administration of Odefsey and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Uočeno je da istodobna primjena Odefsey i lijekova koji induciraju CYP3A smanjuje koncentracije rilpivirina u plazmi što bi potencijalno moglo dovesti do gubitka virološkog odgovora na lijek Odefsey (vidjeti dio 4.3) i moguće rezistencije na rilpivirin i na klasu NNRTI.
Co-administration of Odefsey with other medicinal products that inhibit P-gp (e.g. ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Očekuje se da će istodobna primjena lijeka Odefsey s drugim lijekovima koji inhibiraju P-gp (npr. ketokonazol, flukonazol, itrakonazol, posakonazol, vorikonazol, ciklosporin) povećati apsorpciju i koncentraciju tenofoviralafenamida u plazmi.
Co-administration of Odefsey with proton pump inhibitors has been observed to decrease the plasma concentrations of rilpivirine (due to an increase in gastric pH) which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Uočeno je da istodobna primjena lijeka Odefsey i inhibitora protonske pumpe smanjuje koncentracije rilpivirina u plazmi (zbog porasta želučanih pH-vrijednosti) što bi potencijalno moglo dovesti do gubitka virološkog odgovora na lijek Odefsey (vidjeti dio 4.3) i moguće rezistencije na rilpivirin i na klasu NNRTI.
Co-administration of OLYSIO with ciclosporin is not recommended as this leads to significantly higher exposure of simeprevir based on interim data from an ongoing phase 2 study in HCV infected post-liver transplant patients (see section 4.5).
Istodobna primjena lijeka OLYSIO s ciklosporinom ne preporučuje se jer dovodi do značajno višoj izloženosti simepreviru, temeljeno na privremenim podacima iz ispitivanja faze 2 koje traje, u bolesnika nakon transplantacije jetre koji su inficirani HCV-om (vidjeti dio 4.5).
Co-administration of OLYSIO with substances that moderately or strongly induce or inhibit cytochrome P450 3A (CYP3A4) is not recommended as this may lead to significantly lower or higher exposure of simeprevir, respectively.
Istovremena primjena lijeka OLYSIO s tvarima koje umjereno ili jako induciraju ili inhibiraju citokrom P450 3A (CYP3A4) se ne preporučuje jer može dovesti do značajno niže odnosno više izloženosti simepreviru.